Based on the recent reports of World Health Organization, increased antibiotic resistance
prevalence among bacteria represents the greatest challenge to human health. In addition …

The purpose of this review is to summarize essential pharmacological, pharmaceutical, and
clinical aspects in the field of orally inhaled therapies that may help scientists seeking to …

The management of difficult-to-treat acute and chronic respiratory infections (infections in
cystic fibrosis, non-cystic fibrosis bronchiectasis, immunocompromised and mechanically …

Although new inhaled antibiotics have profoundly improved respiratory diseases in cystic
fibrosis (CF) patients, lung infections are still the leading cause of death. Inhaled antibiotics …

The treatment of lung infection in the context of cystic fibrosis (CF) is limited by a biofilm
mode of growth of pathogenic organisms. When compared to planktonically grown bacteria …

Although antibiotics have been indispensable in the advancement of modern medicine,
there are downsides to their use. Growing resistance to broad-spectrum antibiotics is …

Respiratory disorders are among the most important medical problems threatening human
life. The conventional therapeutics for respiratory disorders are hindered by insufficient drug …

Background Inhaled antibiotics are commonly used to treat persistent airway infection with
Pseudomonas aeruginosa that contributes to lung damage in people with cystic fibrosis …

Characterized by impaired mucus transport and subsequent enhanced colonization of
bacteria, pulmonary infection causes major morbidity and mortality in patients with cystic …

Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen that causes high
morbidity and mortality in cystic fibrosis (CF) and immunocompromised patients, including …